<DOC>
	<DOCNO>NCT00910299</DOCNO>
	<brief_summary>To determine efficacy prasugrel versus clopidogrel reduction adverse cardiovascular outcome patient high platelet reactivity clopidogrel successful implantation coronary drug-eluting stent . To determine adverse event profile prasugrel patient high platelet reactivity clopidogrel implantation coronary drug-eluting stent . To determine effect prasugrel inhibition platelet activation patient high platelet reactivity clopidogrel .</brief_summary>
	<brief_title>Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement Clopidogrel Guide Alternative Therapy With Prasugrel ( TRIGGER-PCI )</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<criteria>Key Have coronary artery disease clinical indication percutaneous coronary intervention ( PCI ) implantation least one drugeluting stent percutaneous coronary intervention treat lesion successful . Have give standardofcare clopidogrel 600mg load dose 24 hour time PCI . Standard Care Aspirin use prior PCI least 250mg [ intravenous ( IV ) oral ] within 24 hour PCI time PCI . VerifyNow P2Y12 reaction unit &gt; 208 measure 27 hour clopidogrel maintenance dose day successful PCI . NonST segment elevation myocardial infarction within 14 day prior randomization STsegment elevation myocardial infarction within 14 day prior randomization Have know major complication percutaneous coronary intervention prior randomization Have body weight &lt; 60 kilogram ( kg ) Have cardiogenic shock time randomization Have refractory ventricular arrhythmia Have New York Heart Association Class IV congestive heart failure Have receive glycoprotein ( GP ) IIb/IIIa inhibitor eptifibatide tirofiban within 24 hr percutaneous coronary intervention abciximab within 10 day percutaneous coronary intervention Are receive daily treatment nonsteroidal antiinflammatory drug ( NSAIDs ) cyclooxygenase2 ( COX2 ) inhibitor discontinue anticipated require &gt; 2 week daily treatment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Clopidogrel</keyword>
	<keyword>VerifyNow</keyword>
	<keyword>PRU Measurements</keyword>
	<keyword>Drug Eluting Stents ( DES )</keyword>
	<keyword>Heart Disease</keyword>
	<keyword>Percutaneous Coronary Intervention ( PCI )</keyword>
	<keyword>P2Y12</keyword>
	<keyword>Platelets</keyword>
	<keyword>Platelet Reactivity</keyword>
</DOC>